Lung Therapeutics, Inc.

Lung Therapeutics, Inc. Lung Therapeutics, Inc. is a pharmaceutical company targeting niche, orphan drug indications for lun

is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Current efforts are focused on a severe complication of pneumonia, called loculated pleural effusion, a debilitating condition where fluid has built up in the chest cavity surrounding the lungs and fibrinous scar tissue in the pleural cavity blocks fluid drainage. Our fir

st product, LTI-01 (single chain urokinase plasminogen activator, or scuPA), is being studied for safe clearance of fibrinous scar tissue in patients with loculated pleural effusion. By clearing the fibrinous buildup pharmaceutically, the clinical pathway for these patients is significantly improved, enabling simple draining of pleural fluid without surgery. Our longer-term efforts will target improvement of clinical pathways for Acute Lung Injury, Idiopathic Pulmonary Fibrosis and other disease conditions.

Address

3801 S. Capital Of Texas Highway, Suite 330
Austin, TX
78704

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+17378021989

Website

Alerts

Be the first to know and let us send you an email when Lung Therapeutics, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Category